Previous Next

Genentech – Product Operations Facility

This campus houses one of the most advanced facilities of its type in the world, setting new standards not only for biotech process design and automation but also in project execution and delivery. Since its completion, this 90,000-liter-capacity facility has produced significant cancer and arthritis therapies for the U.S. and the world. While all mammalian process-based, the facility has thrived in its ability to campaign manufacture the blockbuster drugs Rituxan (first ever FDA approved biotech therapy for cancer), Avastin and Actemra.

FPBA created an inspiring, worker-friendly campus with flexibility for unknown growth. It also master planned an expandable campus (up to 1.2 million square feet) supported by a central utility “spine” to which future buildings could be readily connected. The result of this project is a large-scale, integrated biotech manufacturing campus that was master planned in a design/build collaborative effort with the client, contractors and many engineering disciplines to handle the profound special needs of its client and the biopharmaceutical industry.

Location

Oceanside, CA

Square Footage

512,000 (phase 1)

Team Members

Jim Ferguson
Phil Pape
Andy Darragh
Ken Baldwin
Allan Trowbridge
Axel Probst

Awards

Facility of Year Award by the International Society of Pharmaceutical Engineering (ISPE)

Excellence in Structural Engineering by the Structural Engineering Association